相关实验视频
Updated: Jun 11, 2026

12:36
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
Published on: March 14, 2020
16.0K
硫福拉在肝脏疾病中的治疗潜力:一篇综述
1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Frontiers in pharmacology
|September 14, 2023
概括
硫氨酸 (SFN) 通过减少炎症和氧化应激,显示出治疗脂肪肝和癌症等肝脏疾病的前景. 需要进一步的研究,以克服其有效治疗用途的交付挑战.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝脏疾病,包括代谢相关的脂肪肝病和肝细胞癌,构成日益增长的全球健康负担.
- 目前针对这些疾病的药理疗法有限,需要探索新型治疗剂.
研究的目的:
- 综合审查硫 (SFN) 在治疗常见肝病中的治疗潜力.
- 阐明SFN肝脏保护作用的潜在机制.
- 讨论SFN发展作为肝病治疗的挑战和未来方向.
主要方法:
- 关于硫黄 (SFN) 和肝脏疾病的最新科学文献的综述.
- 对研究SFN的生物活性,包括抗氧化,抗炎和抗癌作用的研究分析.
- 检查有关SFN安全性和生物可用性的临床数据.
主要成果:
- SFN在改善肝肥胖症,预防脂肪肝发育和改善胰岛素敏感性方面表现出显著的疗效.
- SFN表现出强大的抗氧化,抗炎和抗癌特性,包括诱导亡和抑制肝瘤细胞增殖.
- 临床研究证实了SFN在人类中的安全性和良好的耐受性.
结论:
- 由于其多方面的保护机制,SFN是治疗肝脏疾病的有希望的候选人.
- 诸如SFN的不稳定性,水溶性差和可变生物利用性等挑战需要创新的策略来实现其有效的临床应用.
- 对SFN输送系统的进一步研究对于实现其在肝脏保护方面的全部治疗潜力至关重要.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Liver Regeneration
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

